About
Monoclonal Antibodies, Fusion Proteins, Biologics
Areas of Focus
Categories
BiosimilarsBiologics & BiopharmaceuticalAntibodyChina
Clinical Trials (24)
View allTotal Trials
24
As Lead Sponsor
24
As Collaborator
0
Total Enrollment
3,329
By Phase
PHASE1: 13PHASE1/PHASE2: 3PHASE3: 4PHASE2: 4
By Status
UNKNOWN: 18COMPLETED: 4NOT_YET_RECRUITING: 1RECRUITING: 1
Clinical Trials Pipeline24 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06934616Lead Sponsor
A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors
PHASE1Not yet recruiting
330 participants
Started: Apr 24, 2025 · Completed: Mar 31, 2028
NCT05860582Lead Sponsor
A Study of [14C]GB491 in Male Healthy Subjects
PHASE1Completed
6 participants
Started: Sep 14, 2022 · Completed: Nov 14, 2022
NCT05332574Lead Sponsor
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor
PHASE1/PHASE2Unknown
120 participants
Started: May 17, 2022 · Completed: Jun 30, 2025
NCT05851014Lead Sponsor
A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
PHASE3Recruiting
350 participants
Started: Jan 14, 2022 · Completed: Jan 30, 2027
NCT05054751Lead Sponsor
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
PHASE3Completed
275 participants
Started: Sep 10, 2021 · Completed: Mar 30, 2024
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...